Stamford-headquartered Sema4 has introduced a line of genomic testing services and digital tools designed to aid oncologists treating cancer patients from the risk assessment to the remission monitoring process.
The new offerings include whole exome sequencing for tumor and normal samples and whole transcriptome sequencing for tumor samples only. The new digital tools are designed for use with FFPE, bone marrow, blood or saliva samples, and are built on Sema4”™s Centrellis health intelligence platform. These include Patient Journey, which provides an interactive timeline visualization of the patient”™s total treatment experience; Cohort Builder, which defines groups of patients according to specific parameters in order to analyze treatment patterns and identify appropriate clinical trials; and VONC, an automated variant curation platform that culls multiple databases to support curation of genetic information to inform therapy decisions.
Sema4 is previewing the new offerings at the American Society for Clinical Oncology 2019 Annual Meeting, which begins today in Chicago and runs through June 4.
“Sema4”™s mission to help physicians implement precision medicine is built on our deep foundation in data science and developing genomic tests,” said Eric Schadt, founder and CEO of Sema4. “Our team”™s expertise in data mining, analysis, machine learning, and predictive modeling gives us a unique advantage in generating and making sense of information in ways that will give oncologists an edge in battling cancer, particularly when combined with advanced genomic profiling.”
